(VIANEWS) – SPAREBANKEN VEST (SVEG.OL), ALTRI SGPS (ALTR.LS), MEDISTIM (MEDI.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPAREBANKEN VEST (SVEG.OL)
32.2% sales growth and 13.51% return on equity
Sparebanken Vest, a financial services company, provides banking and financing services in the counties of Vestland and Rogaland, Norway. It operates through Corporate Market, Retail Market, Bulder Bank, Treasury, and Estate Agency Activities segments. The company is also involved in the estate agency and home mortgage activities. The company was founded in 1823 and is headquartered in Bergen, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN VEST has a trailing twelve months EPS of kr7.36.
PE Ratio
SPAREBANKEN VEST has a trailing twelve months price to earnings ratio of 12.55. Meaning, the purchaser of the share is investing kr12.55 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.51%.
Moving Average
SPAREBANKEN VEST’s worth is below its 50-day moving average of kr95.41 and higher than its 200-day moving average of kr90.40.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 9.4% and 35.3%, respectively.
More news about SPAREBANKEN VEST.
2. ALTRI SGPS (ALTR.LS)
16% sales growth and 24.22% return on equity
Altri, SGPS, S.A. produces and sells bleached eucalyptus pulp in Portugal and internationally. It offers bleached eucalyptus kraft pulp for use in a range of papers, such as tissues, and printing and writing papers; and dissolving pulp for use in textile production. The company is also involved timber commercialization; forest management; the production of energy from forest resources, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.
Earnings Per Share
As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.17.
PE Ratio
ALTRI SGPS has a trailing twelve months price to earnings ratio of 28.21. Meaning, the purchaser of the share is investing €28.21 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.22%.
Sales Growth
ALTRI SGPS’s sales growth is 73.9% for the current quarter and 16% for the next.
Moving Average
ALTRI SGPS’s worth is below its 50-day moving average of €4.82 and way under its 200-day moving average of €5.48.
More news about ALTRI SGPS.
3. MEDISTIM (MEDI.OL)
10.2% sales growth and 33.83% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr3.84.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 73.94. Meaning, the purchaser of the share is investing kr73.94 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 491.94M for the twelve trailing months.
More news about MEDISTIM.
